Globe Newswire

Invalda INVL had equity of EUR 182.8 million at the end of March 2024, or EUR 15.23 per share. The figures were 39% and 37% larger, respectively, than a year earlier.

Invalda INVL had an unaudited net profit of EUR 4.7 million in the first quarter of the year, which is 4.1 times more than the same period last year when net profit amounted to EUR 1.1 million.

“It was an ordinary quarter. We worked actively with our assets under management and new opportunities,... (continue reading...)

In the first quarter of 2024, AUGA group, AB and its subsidiaries (hereinafter – the Group) had sales revenue of EUR 19.74 million, compared to EUR 19.96 million in the same period of 2023.

The Group's gross profit in the first quarter of 2024 was EUR 2.71 million, compared to EUR 1.90 million a year earlier. The Group's EBITDA in the reporting period was EUR 4.26 million. In the same period last year it was EUR 2.68 million.

"The financial results for the first... (continue reading...)

MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Thursday, June 6th at 10:30 a.m. Eastern time.

The fireside chat will be webcast live and available for replay in... (continue reading...)

COPENHAGEN, Denmark, May 31, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of a freeze-dried formulation of JYNNEOS® for prevention of smallpox and mpox disease in adults 18 years of age and older.

The liquid-frozen formulation of JYNNEOS® was approved by the FDA in September 2019. It remains the only approved mpox vaccine... (continue reading...)

PRESS RELEASE

SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

Paris, May 31, 2024, 4.30pm CET

AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in the treatment... (continue reading...)